Global & France Cancer Therapeutics Market to 2031

A Le Monde article published in March 2023 highlighted that the proportion of France’s population aged 60 and over is projected to increase from approximately 20% in 2023 to around 30% by 2050. The number of individuals aged 85 and older is projected to increase by nearly 90% between 2030 and 2050. This growing elderly population is a significant factor contributing to the expansion of the cancer therapeutics market, as older adults have a higher risk of developing cancer. As a result, there is a growing need for advanced therapies, personalized treatment approaches, and comprehensive supportive care, motivating pharmaceutical companies to ramp up research and development efforts.

According to GLOBOCAN 2022 data, France recorded about 58,083 new breast cancer cases, making up 12.4% of all cancer diagnoses in the country. The five-year prevalence rate across all age groups stood at 702.58 per 100,000 people. Breast cancer also emerged as the leading cause of cancer-related deaths among women, accounting for 14,183 deaths in 2022. The rising prevalence of breast cancer is fueling demand for innovative treatment solutions, including targeted therapies and immunotherapies, further driving pharmaceutical investment in R&D and contributing to overall market expansion.

To maintain a competitive edge and deliver state-of-the-art treatments, pharmaceutical companies are increasingly focusing on innovation. For instance, in November 2021, Sanofi committed US$180 million to a strategic partnership with Owkin, a French–American AI company specializing in cancer research and drug development. As part of the deal, Sanofi made a US$90 million payment to support research into four specific cancer types. This collaboration aims to strengthen Sanofi’s oncology pipeline in key areas such as breast cancer, lung cancer, and multiple myeloma by improving clinical trial strategies and identifying predictive biomarkers for more precise diagnoses and treatment plans. Show more